ArticleThe pharmacogenomics journal2017

CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy.

S Matsusaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.